Biohaven highlights portfolio progress, innovation, and anticipated milestones at the 43rd annual j.p. morgan healthcare conference; reports positive degrader data with rapid, deep, and selective lowering of galactose-deficient iga1 with next generation potential therapy for iga nephropathy

Presents progress and new anticipated milestones across portfolio of more than 10 assets and 6 therapeutic areas. announces multiple advancements across the modetm (molecular degraders of extracellular proteins) platform and the next generation traptm (targeted removal of aberrant protein) degraders, including: iga nephropathy (igan) program: first-in-human dosing with bhv-1400, a next generation trap degrader, achieved rapi­d, deep, and selective lowering of only aberrant galactose-deficient iga1 (gd-iga1), the antibody causing iga nephropathy, while sparing normal iga.
BHVN Ratings Summary
BHVN Quant Ranking